Navigation Links
Four Out of Five BioSpain 2012 Participants Identified Genuine Business Opportunities
Date:3/5/2013

MADRID, March 5, 2013 /PRNewswire/ --

A survey reveals visitor satisfaction of 93%, while 97% would be interesting in attending future editions of the fair.

BioSpain 2012, held in Bilbao in September 2012, has strengthened its position as the principal platform for creating business opportunities in Spain's biotechnology sector. A survey by the organisation reveals that 77% of BioSpain 2012 participants identified genuine business opportunities at the event. This aligns with the objectives established by the organisation, which aims for BioSpain to drive the industry in the current adverse economic situation.

As regards general satisfaction, 93% rated the event positively and 88% stated that it had met their expectations; networking was the most highly-valued activity. In fact, partnering at this year's three-day event led to a record 2,775 one-on-one meetings, making it the fifth-largest international event of its type in terms of networking.

Moreover, 97% of those meetings are expected to lead to a second meeting at a later date. Partnering and one-on-one meetings at BioSpain are increasingly viewed as positive because of the technology available to participants; this year more than 643 technologies and products were on offer (22% more than at the previous edition, in 2010).

The survey also provides useful information regarding biotechnology firms' priorities in this adverse economic environment. The main objective of 48% of BioSpain 2012 participants was to identify R&D collaboration opportunities. Other goals were to attract potential clients (46%), learn about the latest trends and technology (32%) and study the competition (26%).

With respect to the future, 97% of participants will consider attending the next edition of BioSpain in 2014 (venue to be determined).

Click on the link below for the survey results: http://www.asebio.com/documents/resultados_encuesta_para_web_asebio.pdf

Further information from:
Lucía Cecilia
Head of Communication at BioSpain 2012 and ASEBIO
Tel:    +34-912109374/10
Mobile: +34-663117293    
e-mail: lcecilia@asebio.com
http://www.asebio.com


'/>"/>
SOURCE BioSpain 2012 Committee Organization
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpain 2012 is Larger in Terms of Internationalisation and the Number of Exhibitors, Meetings and Visitors
2. CAS Names 2012 SciFinder® Future Leaders in Chemistry Program Participants
3. Carin Grings remains identified by researchers at Uppsala University
4. Genuine Bio-Fuel Clears the Air About Biodiesel In Wake of Recent Turmoil
5. Genuine Bio-Fuel Inc. Notes Sustainable Energy Gets A Much Needed Boost from the President Obama During 2013 Inaugural Address
6. Genuine Bio-Fuel Inc. Expands Operations to Puerto Rico
7. Bentley Receives $1.3M to Advance the Integration of Science and Business
8. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
9. BIOCOM Names Rick Fultz Vice President of Business Development
10. Pamlab Announces Agreement for Sale of Business to Nestle Health Science
11. Local Leaders Convene in Boston to Share Industry Best Practices in Second “Business of Big Data” Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017   Sienna Biopharmaceuticals, Inc. , a privately ... that Richard Peterson will join the company ... Peterson, who brings more than two decades of global ... is retiring at the end of April but will ... joins Sienna from Novan, Inc., where he served as ...
(Date:3/23/2017)... BETHESDA, Md. , March 23, 2017 /PRNewswire/ ... company developing DCVax® personalized immune therapies for solid ... on the $7.5 million financing it announced last ... Company sold to several institutional investors securities totaling ... $.26 per share, and 10,000,000 shares of Class ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced ... the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business ... joint development activities. , “Dr. Floyd’s career has spanned 30 years in the ...
Breaking Biology Technology:
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
Breaking Biology News(10 mins):